Body Weight Cycling Tied to Increased Risk for Renal Events in Type 1 Diabetes
By Elana Gotkine HealthDay Reporter
MONDAY, Feb. 10, 2025 -- For individuals with type 1 diabetes, intraindividual body weight variability, or body weight cycling, is associated with an increased risk for renal events, according to a study published online Feb. 4 in the Journal of Clinical Endocrinology & Metabolism.
Marion Camoin, M.D., from the Assistance Publique–Hôpitaux de Paris, and colleagues conducted a retrospective analysis of data from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) studies to examine the association between body weight cycling and risk for renal events among patients with type 1 diabetes. Four indices of intraindividual body weight variability were calculated for 1,432 participants of the DCCT/EDIC studies; variability independent of the mean (VIM) was the main index. During follow-up (21 ± four years), six criteria of progression of chronic kidney disease (CKD) were studied.
The researchers found that a high VIM was significantly associated with the incidence of a 40 percent decline in estimated glomerular filtration rate (eGFR) from baseline values, doubling of baseline serum creatinine, CKD stage 3, and a decline in eGFR >3 mL/min/m2 per year after adjustment for CKD risk factors at baseline and follow-up and use of nephroprotective drugs. There was also an association seen for VIM with incidence of moderately and severely increased albuminuria, but after adjustment for follow-up covariates, the associations were no longer significant. For the other indices of body weight cycling, similar results were observed.
"Strategies aimed at weight reduction in people with type 1 diabetes should focus on promoting long-term weight maintenance, as weight stability may have a positive impact on health outcomes," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Doctors Favor CPAP, Patients Favor Tirzepatide for Comorbid Obesity, Sleep Apnea
MONDAY, June 9, 2025 -- Both continuous positive airway pressure (CPAP) and tirzepatide are acceptable treatments for comorbid obesity and obstructive sleep apnea (COBOSA), with...
Finerenone + Empagliflozin Offers Greater Benefit in CKD, T2DM
MONDAY, June 9, 2025 -- For patients with chronic kidney disease and type 2 diabetes, combination finerenone plus empagliflozin leads to a greater reduction in the urinary...
Less 'Experienced Weight Stigma' After Bariatric Surgery Aids Mental Health
FRIDAY, June 6, 2025 -- Experienced weight stigma (EWS) improves from pre- to post-metabolic bariatric surgery (MBS), according to a study published online June 5 in Health...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.